HRS9531 Injection Placebo
Phase 2
HRS9531 Injection Placebo is one of 4 therapeutic programs targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
#DrugCompanyPhaseTrials
1HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
ALN-HSD
Alnylam PharmaceuticalsPhase 2
HRS9531 Injection Placebo
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
LY3849891
Eli LillyPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for HRS9531 Injection Placebo. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]